Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Tomoaki Matsumura, Michiko Sonoda, Kenichiro Okimoto, Hang Viet Dao, Satsuki Takahashi, Naoki Akizue, Ryosuke Horio, Chihiro Goto, Akane Kurosugi, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Jun Kato, Naoya Kato
BACKGROUND: Vonoprazan, a potassium-competitive acid blocker, demonstrates more potent acid inhibition than proton pump inhibitors (PPIs). This study aimed to evaluate the effect of vonoprazan in patients with unproven gastroesophageal reflux disease (GERD) by comparing patients with vonoprazan-refractory heartburn with those with PPI-refractory heartburn. METHODS: This study included 104 consecutive patients with vonoprazan- or PPI-refractory heartburn (52 patients each), no erosive esophagitis on endoscopy and who underwent combined multichannel intraluminal impedance-pH (MII-pH) testing with vonoprazan/PPI discontinuation...
April 15, 2024: Digestive Diseases and Sciences
#22
JOURNAL ARTICLE
Sama Anvari, Kayla Dadgar, Ciarán Galts, Michael Bretthauer
This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding...
April 16, 2024: Annals of Internal Medicine
#23
JOURNAL ARTICLE
Brian E Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson, Rebecca Bungay, Remi Bellefleur, Annie Guérin, Brock Bumpass, Danellys Borroto, George Joseph, Ankur A Dashputre
INTRODUCTION: Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA. METHODS: Adult patients (18-64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics® Plus database (10/01/2015-12/31/2021) and classified into two mutually exclusive cohorts (i...
April 15, 2024: Advances in Therapy
#24
JOURNAL ARTICLE
Zahra Alawi, Wadeeah AlMakna, Fatema Hassan, Marwa Faisal, Hawra Matar, Adel S Alsayyad
BACKGROUND: Irritable bowel syndrome (IBS) is a very common gastrointestinal disorder encountered in clinical practice. In this study, we estimated the prevalence of isolated IBS and its associated demographic factors among the adult population in the Kingdom of Bahrain. METHODS: A cross-sectional study was conducted targeting adults in Bahrain aged 18 years and above. Individuals with a prior diagnosis of any bowel ailment were excluded. Data was acquired via a self-administered questionnaire...
March 2024: Curēus
#25
REVIEW
Prashant Singh, Gregory S Sayuk, David P Rosenbaum, Susan Edelstein, Kenji Kozuka, Lin Chang
BACKGROUND: Patients with irritable bowel syndrome with constipation (IBS-C) experience persistent abdominal pain, a common symptom leading to greater healthcare utilization and reports of treatment non-response. Clinically significant improvements in abdominal pain were observed in clinical trials of tenapanor, a first-in-class inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), for the treatment of IBS-C in adults. AIM: This narrative review reports the current knowledge about visceral hypersensitivity as a mechanism for abdominal pain in patients with IBS-C and explores the published evidence for hypothesized mechanisms by which tenapanor may reduce visceral hypersensitivity leading to the observed clinical response of decreased abdominal pain...
2024: Clinical and Experimental Gastroenterology
#26
REVIEW
Xiaoli Chang, Haiyan Zhang, Shaozong Chen
Visceral hypersensitivity, a common clinical manifestation of irritable bowel syndrome, may contribute to the development of chronic visceral pain, which is a major challenge for both patients and health providers. Neural circuits in the brain encode, store, and transfer pain information across brain regions. In this review, we focus on the anterior cingulate cortex and paraventricular nucleus of the hypothalamus to highlight the progress in identifying the neural circuits involved in visceral pain. We also discuss several neural circuit mechanisms and emphasize the importance of cross-species, multiangle approaches and the identification of specific neurons in determining the neural circuits that control visceral pain...
April 13, 2024: Communications Biology
#27
REVIEW
Francesca Lusetti, Annalisa Schiepatti, Davide Scalvini, Stiliano Maimaris, Federico Biagi
Background: Persistent symptoms in coeliac disease (CD) can be due to not only poor gluten-free diet (GFD) adherence and complications of CD, but also functional gastrointestinal disorders such as irritable bowel syndrome (IBS). Although the role of a low fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) diet is well-established in IBS, little data are available on its role in coeliac patients with persistent IBS-like symptoms despite a GFD. Methods: We systematically reviewed the literature in accordance with the PRISMA guidelines for studies evaluating the role of FODMAPs and/or a low-FODMAP diet in coeliac patients with persistent symptoms...
April 8, 2024: Nutrients
#28
REVIEW
Giovanna Muscogiuri, Oriana De Marco, Tonia Di Lorenzo, Maria Amicone, Ivana Capuano, Eleonora Riccio, Guido Iaccarino, Antonio Bianco, Teodolinda Di Risi, Antonio Pisani
Fabry disease (FD) is caused by mutations in the galactosidase alpha (GLA) gene which lead to the accumulation of globotriaosylceramide (Gb-3). Enzyme replacement therapy (ERT) and oral chaperone therapy are the current pharmacological treatments for this condition. However, in the literature, there is a growing emphasis on exploring non-pharmacological therapeutic strategies to improve the quality of life of patients with FD. In particular, the nutritional approach to FD has been marginally addressed in the scientific literature, although specific dietary interventions may be useful for the management of nephropathy and gastrointestinal complications, which are often present in patients with FD...
April 4, 2024: Nutrients
#29
JOURNAL ARTICLE
Fatima Maqoud, Antonella Orlando, Domenico Tricarico, Marina Antonacci, Annamaria Di Turi, Gianluigi Giannelli, Francesco Russo
Natural compounds like flavonoids preserve intestinal mucosal integrity through their antioxidant, anti-inflammatory, and antimicrobial properties. Additionally, some flavonoids show prebiotic abilities, promoting the growth and activity of beneficial gut bacteria. This study investigates the protective impact of Lens culinaris extract (LE), which is abundant in flavonoids, on intestinal mucosal integrity during LPS-induced inflammation. Using Caco-2 cells as a model for the intestinal barrier, the study found that LE did not affect cell viability but played a cytoprotective role in the presence of LPS...
March 28, 2024: International Journal of Molecular Sciences
#30
JOURNAL ARTICLE
Hye-Youn Kim, Cho-Een Kim, Dool-Ri Oh, Yonguk Kim, Chul-Yung Choi, Jaeyong Kim
Irritable bowel syndrome (IBS), a common gastrointestinal disorder worldwide, is characterized by chronic abdominal pain, bloating, and disordered defecation. IBS is associated with several factors, including visceral hypersensitivity, gut motility, and gut-brain interaction disorders. Because currently available pharmacological treatments cannot adequately improve symptoms and may cause adverse effects, the use of herbal therapies for managing IBS is increasing. Lysimachia vulgaris var. davurica (LV) is a medicinal plant used in traditional medicine to treat diarrhea...
March 27, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
#31
JOURNAL ARTICLE
Aurelio Seidita, Alessandra Giuliano, Maurizio Soresi, Marta Chiavetta, Emilio Nardi, Giuseppe Mogavero, Giulio Giannone, Antonio Carroccio, Pasquale Mansueto
Some data suggest the existence of intestinal inflammation in patients with non-celiac wheat sensitivity (NCWS). We aimed to verify whether fecal calprotectin (FCP), a marker of intestinal inflammation, could be used to confirm this inflammatory status and to test its diagnostic performance in differentiating NCWS from irritable bowel syndrome/functional dyspepsia (IBS/FD). We conducted a multicenter study, comparing NCWS patients, diagnosed by a double-blind placebo-controlled wheat challenge, with IBS/FD subjects...
April 12, 2024: Internal and Emergency Medicine
#32
JOURNAL ARTICLE
Masatomo Ishioh, Tsukasa Nozu, Saori Miyagishi, Sho Igarashi, Takuya Funayama, Nobuhiro Ueno, Toshikatsu Okumura
Intestinal barrier dysfunction, leaky gut, is implicated in various diseases, including irritable bowel syndrome (IBS) and neurodegenerative conditions like Alzheimer's disease. Our recent investigation revealed that basal forebrain cholinergic neurons (BFCNs), critical for cognitive function, receive signals from butyrate and orexin, playing a role in regulating intestinal barrier function through adenosine A2B signaling and the vagus. This study explores the involvement and function of brain histamine, linked to BFCNs, in the regulation of intestinal barrier function...
April 10, 2024: Biochemical Pharmacology
#33
JOURNAL ARTICLE
Nessmah Sultan, Mandy Foyster, Matilda Tonkovic, Danielle Noon, Helen Burton-Murray, Jessica R Biesiekierski, Caroline J Tuck
INTRODUCTION: Orthorexia, a harmful obsession with eating healthily, may develop from illnesses characterized by dietary restriction, including irritable bowel syndrome (IBS) and eating disorders (ED). Evidence of disordered eating in IBS exists, but orthorexia has not been assessed. This cross-sectional study in adults (≥18 years) assessed presence and characteristics of disordered eating and orthorexia in IBS, compared to control subjects (CS) and ED. METHODS: IBS participants met Rome IV, and ED participants met DSM-5 criteria...
April 12, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#34
JOURNAL ARTICLE
Facundo Pereyra, Luis María Bustos Fernández, Francisco Schlottmann, Rafael Zamora, Agustina Marconi, Leandro Steinberg, Lisandro Pereyra
BACKGROUND: Irritable bowel syndrome (IBS) is a functional disorder commonly associated with extra-intestinal symptoms. However, the prevalence of these symptoms according to IBS subtype is not well established. AIM: To compare the prevalence of extra-intestinal symptoms among patients with different subtypes of IBS. METHODS: A descriptive cross-sectional study including patients with IBS according to Rome IV criteria was performed between July 2022 and April 2023...
April 12, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#35
JOURNAL ARTICLE
Nastasia Mattio, Pierre Pradat, Christelle Machon, Anne Mialon, Sabine Roman, Charlotte Cuerq, François Mion
BACKGROUND: Glucose breath test (GBT) is used for the diagnosis of small intestine bacterial overgrowth. A restrictive diet without fibers and/or fermentable food is recommended on the day before the test. The aim of our retrospective study was to evaluate the impact of two different restrictive diets on the results of GBT. METHODS: A change of the pretest restrictive diet was applied in our lab on September 1, 2020. The recommended diet was a fiber-free diet before this date, and a fiber-free diet plus restriction of all fermentable food afterward...
April 12, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#36
JOURNAL ARTICLE
Jiaying Li, Daniel Yee Tak Fong, Kris Yuet Wan Lok, Janet Yuen Ha Wong, Mandy Man Ho, Edmond Pui Hang Choi, Vinciya Pandian, Patricia M Davidson, Wenjie Duan, Marie Tarrant, Jung Jae Lee, Chia-Chin Lin, Oluwadamilare Akingbade, Khalid M Alabdulwahhab, Mohammad Shakil Ahmad, Mohamed Alboraie, Meshari A Alzahrani, Anil S Bilimale, Sawitree Boonpatcharanon, Samuel Byiringiro, Muhammad Kamil Che Hasan, Luisa Clausi Schettini, Walter Corzo, Josephine M De Leon, Anjanette S De Leon, Hiba Deek, Fabio Efficace, Mayssah A El Nayal, Fathiya El-Raey, Eduardo Ensaldo-Carrasco, Pilar Escotorin, Oluwadamilola Agnes Fadodun, Israel Opeyemi Fawole, Yong-Shian Shawn Goh, Devi Irawan, Naimah Ebrahim Khan, Binu Koirala, Ashish Krishna, Cannas Kwok, Tung Thanh Le, Daniela Giambruno Leal, Miguel Ángel Lezana-Fernández, Emery Manirambona, Leandro Cruz Mantoani, Fernando Meneses-González, Iman Elmahdi Mohamed, Madeleine Mukeshimana, Chinh Thi Minh Nguyen, Huong Thi Thanh Nguyen, Khanh Thi Nguyen, Son Truong Nguyen, Mohd Said Nurumal, Aimable Nzabonimana, Nagla Abdelrahim Mohamed Ahmed Omer, Oluwabunmi Ogungbe, Angela Chiu Yin Poon, Areli Reséndiz-Rodriguez, Busayasachee Puang-Ngern, Ceryl G Sagun, Riyaz Ahmed Shaik, Nikhil Gauri Shankar, Kathrin Sommer, Edgardo Toro, Hanh Thi Hong Tran, Elvira L Urgel, Emmanuel Uwiringiyimana, Tita Vanichbuncha, Naglaa Youssef
BACKGROUND: Central and bridge nodes can drive significant overall improvements within their respective networks. We aimed to identify them in 16 prevalent chronic diseases during the coronavirus disease 2019 (COVID-19) pandemic to guide effective intervention strategies and appropriate resource allocation for most significant holistic lifestyle and health improvements. METHODS: We surveyed 16 512 adults from July 2020 to August 2021 in 30 territories. Participants self-reported their medical histories and the perceived impact of COVID-19 on 18 lifestyle factors and 13 health outcomes...
April 12, 2024: Journal of Global Health
#37
Regen K Morgan, Austin Wynn, Mary K Hanisee
Pneumatosis cystoides intestinalis (PCI) is a rare condition characterized by gas-filled cysts that develop in the mucosal and submucosal layers of the digestive tract. PCI is typically a benign disease but complications can occur that require surgical intervention. This patient presented to the emergency department with a two-day history of abdominal and back pain. A contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis led to suspicion of free intraperitoneal air potentially due to bowel perforation, and exploratory laparotomy was indicated...
March 2024: Curēus
#38
REVIEW
Andreas Stallmach, Stefanie Quickert, Christian Puta, Philipp A Reuken
Like other infections, a SARS-CoV-2 infection can also trigger Post-Acute Infection Syndromes (PAIS), which often progress into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS, characterized by post-exercise malaise (PEM), is a severe multisystemic disease for which specific diagnostic markers or therapeutic concepts have not been established. Despite numerous indications of post-infectious neurological, immunological, endocrinal, and metabolic deviations, the exact causes and pathophysiology remain unclear...
2024: Frontiers in Immunology
#39
JOURNAL ARTICLE
Faezeh Shafiei, Mahmood Dehghani, Fahimeh Fathali Lavasani, Mehdi Manouchehri, Marjan Mokhtare
Studies have provided evidence for the effectiveness of intensive short-term dynamic psychotherapy (ISTDP) in treating medically unexplained symptoms (MUS). This study aimed to examine the effectiveness of ISTDP on individuals living with irritable bowel syndrome (IBS) in terms of, emotion regulation (ER) abilities, defense mechanisms, quality of life (QOL), and IBS symptoms. A total of 30 patients diagnosed with IBS were recruited and randomly assigned to either the intervention ( n = 15) or control ( n = 15) group...
2024: Frontiers in Psychology
#40
JOURNAL ARTICLE
Motasem M Alsmadi, Alla A Abudaqqa, Nasir Idkaidek, Nidal A Qinna, Ahmad Al-Ghazawi
The common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model...
April 11, 2024: AAPS PharmSciTech
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
